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The microbial ecosystem of the gastrointestinal tract is characterized by a great number of microbial species liv-
ing in balance by adopting mutualistic strategies. The eubiosis/dysbiosis condition of the gut microbiota strongly 
influences our healthy and disease status. This review briefly describes microbiota composition and functions, to 
then focus on eubiosis and dysbiosis status: the two sides of the microbiota.
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INTrODuCTION
All multicellular organisms live in close asso-
ciation with the surrounding microbes, and 
humans are no an exception. Every part of our 
body surface, in communication with the en-
vironment, its colonized. The number of these 
microorganisms, collectively known as “micro-
biota”, is tenfold higher than that of our cells 
(Sekirov et al., 2006), the human beings are now 
considered as “hybrid organisms” (Sekirov et 
al., 2006), consisting of both human and micro-
bial cells. The coding capacity of microbiota, 
called “microbiome”, is a hundred times higher 
than that of our cells (Ley et al., 2006). Microbes 
colonize our body from birth, and persist until 
death, interfering with our anatomical, physio-
logical and immunological development. After 
a brief description of its composition and func-
tions, we will  look at the strategies activated by 
human and microbes to maintain an eubiosis 
status in the gut microbiota ecosystem.
GuT MICrOBIOTA COMPOSITION  
AND FuNCTIONS
The gastrointestinal tract (GIT) is unquestion-
ably the most populated organ. The colon con-
tains more than 70% of the microorganisms 
colonizing GIT (Sartor, 2008). Taxonomically 
speaking, compared to the 100 and more bac-
terial phyla existing on the planet Earth, only a 
few divisions have been identified in the human 
gut: Firmicutes, Bacteroidetes, Proteobacteria, 
Verrucomicrobia, Actinobacteria and Fusobac-
teria (Zoetendal et al., 2008). Furthermore, 99% 
of the identified species belong mainly to the 
two phyla Firmicutes and Bacteroidetes, rep-
resenting together 70% of the total microbiota 
(Mariat et al., 2009). 
The anaerobic bacteria exceed by two or three 
orders of magnitude the facultative anaerobic 
and aerobic bacteria (Harris et al., 1976). The 
similarity among individuals, observed at phy-
lum taxonomic level, is lost considering the 
taxonomic level of species. Considering the 
gut microbiota at the species taxonomic level, 
we can observe a significant variation among 
individuals (Frank et al., 2007), so that the mi-
crobiota composition could be compared to a 
fingerprint (Eckburg et al., 2005). The diver-
sity among individuals is easily understood if 
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we consider the myriad of factors influencing 
the composition of the intestinal microbial eco-
system. Host genetic background that through 
bacteria attachment sites exert an important 
role for the first colonizing bacteria (pioneer 
flora) arrive. 
Pioneer flora in turn modulates host genes 
expression, influencing the successive micro-
bial flora (Hooper et al., 2001). Moreover en-
vironmental factors, such as age, diet, stress, 
drugs, will strongly influence the composition 
of the human microbiota (Rawls et al., 2006). 
Both endogenous and exogenous factors will 
contribute to the microbiota composition. 
In order to verify the changes in microbiota 
composition in different geographical areas, 
the faecal microbiota of subjects belonging to 
different ethnic groups, states and continents 
were examined (Arumugam et al., 2011). The 
study (Arumugam et al., 2011) highlighted that 
human gut flora can be classified into three 
different groups, named Enterotypes, based 
on variations of specific genera. Specifically: 
Enterotype 1, with a prevalence of the Bac-
teroides; Enterotype 2 with a prevalence of 
Prevotella; Enterotype 3 with a prevalence of 
Ruminococcus. 
There would seem to be no relationship be-
tween Enterotype geographic area, sex, age or 
body mass index (Jeffery et al., 2012). Each En-
terotype has unique properties, but still has a 
number of essential common functions, prob-
ably representing those necessary to survival 
in the intestinal habitat. Even if this finding 
needs to be confirmed, it implies that each En-
terotype has different capabilities, and differ-
ent metabolic responses to diet or medication, 
giving a reason why different persons exhibit 
different responses to medical treatments. 
Complicated symbiotic relations were evolved 
between men and microbes. In general, we 
speak of co-evolution, co-adaptation, and 
co-dependency. The correct term to define 
the kind of relation between men and their 
microbiota is mutualistic (both, human and 
microbes, have their benefit). About 50 years 
ago, the ecologist Theodor Rosebury coined 
the term Amphibiosis (Blaser et al., 2006) to 
define the relationship between humans and 
microbes that could be beneficial or patho-
logical, depending on the context in which it 
occurs. A community highly efficient in recov-
ering energy from food may constitute a risk 
factor for obesity in a person with easy access 
to food, while it may be healthy in an individ-
ual with limited access to food. 
The intestinal microbiota must be consid-
ered a real organ, with well-defined functions, 
composed of different cell lines (represented 
by the different microbes), that communicate 
with each other and with the host, consum-
ing, preserving and redistributing the energy, 
operating physiologically important chemical 
transformations and able to maintain and re-
pair itself by self-replication (Possemiers et al., 
2011). The functions carried out by the gut mi-
crobiota organ include: barrier versus hexogen 
microbes, structural and metabolic functions 
(Hooper et al., 2001; Gill et al., 2006), together 
with an important role in immune system de-
velopment and activation (Kamada et al., 2013; 
Belkaid et al., 2014). Gut microbiota exerts a 
barrier function versus hexogen microbes by 
means of competition phenomena for nutri-
ents and ecological niches (Buffie et al., 2013), 
and production of antimicrobial substances 
(Alakomi et al., 2000). 
The development of the intestinal tract in-
volves the formation of a surface area large 
enough to allow a blood supply appropriate 
for nutrient acquisition, containing a suitable 
number of attachment sites for microbes, and 
able to support the resident bacterial com-
munity. It must also be resistant to systemic 
translocation of foreign antigens and micro-
biota-derived catabolites. In addition, subse-
quent to an injury, it must be able to maintain 
its homeostasis and to restore itself. Several 
studies showed the strong influence of the mi-
crobiota in the development of the gastrointes-
tinal tract. 
Members of the microbiota are able to induce 
the transcription of the angiogenc-3 protein, 
with angiogenic activity (Hooper et al., 2001); 
B. thetaiotaomicron strongly influences the 
transcription of host factors involved in the 
functionality of the enteric nervous system, 
suggesting that it may have a rule in the post-
natal development of peristalsis (Hooper et al., 
2001). Gut microbiota contributes to the main-
tenance of the integrity of the intestinal epithe-
lial barrier through the maintenance of cell-
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cell junctions, and the promotion of epithelial 
repair after damage (Sekirov et al., 2010). Gut 
microbiota intervenes in the structural develop-
ment of the gastrointestinal tract and immune 
system (Kamada et al., 2013). It is therefore 
conceivable that the composition of colonizing 
flora influences immune individual variations 
(Lee et al., 2014). 
Furthermore, several studies indicated the in-
fluence of microbiota on structural develop-
ment and functioning, of organs outside the 
intestinal tract (Sommer et al., 2013). Exper-
iments conducted with germ-free mouse indi-
cate that the microbiota influences the regu-
lation of mood and behaviour, contributes to 
the pathophysiology of the humour disorders 
(Diaz et al., 2011) and influences the develop-
ment of the nervous system. Germ-free mouse 
showed deregulation in the hypothalamic-pi-
tuitary-adrenal axis (HPA) influencing the host 
response to stress, (Nobuyuki et al., 2004), and 
a decreased perception of inflammatory pain.
Our distal intestine is comparable to an an-
aerobic bioreactor, housing most of our intes-
tinal microorganisms and in which otherwise 
indigestible polysaccharides, including those 
derived from plants such as pectin, cellulose, 
hemicellulose, resistant starch are degraded 
(Sonnenburg et al., 2006). Humans contain a 
very limited arsenal of enzymes necessary to di-
gest common polysaccharides, which are pro-
vided by the microbiome (Sonnenburg et al., 
2006). Intestinal microbiota maximizes caloric 
availability of nutrients ingested by:
1) the extraction of additional calories from 
otherwise indigestible oligosaccharides;
2) the modulation of intestinal epithelium ab-
sorption capacity and nutrient metabolism 
(Hooper et al., 2001), thereby promoting the 
absorption of nutrients and their use.
Moreover, the important role of microbiota in 
the metabolism of xenobiotic compounds, such 
as drugs administered for therapeutic purpos-
es, should not be underestimated. Today phar-
maco-genetic examination, essential for the 
production and administration of therapies, 
is a well accepted concept. This notion should 
be extended, and include drug metabolomics, 
which takes into account the contribution to 
drug metabolism of both the host and its mi-
crobiota (Nicholson et al., 2005).
MONITOrING THE MICrOBIOTA
A healthy intestinal microbial ecosystem is bal-
anced but flexible enough to tolerate the intru-
sion of potential pathogens from hexogen flora 
(food, water, and various environmental com-
ponents), normally contained in a regular flow 
condition. A healthy intestinal flora is essential 
to promote the health of the host, but the ex-
cessive growth of the bacterial population leads 
to a variety of harmful conditions. To avoid this 
outcome humans have implemented various 
strategies. The mucosal immune system must 
satisfy two functions:
1) be able to control the intestinal microbiota 
preventing overgrowth and translocation to 
systemic sites (Sekirov et al., 2010);
2) tolerate microbes, and prevent the induction 
of an excessive and injurious systemic im-
mune response.
The excessive growth of the bacterial popu-
lation and the penetration/translocation of 
the microbiota outside its luminal compart-
ment, it is hindered in different ways as the 
production of secretory IgA (Macpherson et 
al., 2004), and antimicrobial peptides (AMPS) 
(Cash et al., 2006; Ostaff et al., 2013). Numer-
ous antimicrobial peptides (AMP), (defensins, 
cathelicidins, lectins, etc.) and diverse groups 
of compounds, acting by breaking the surface 
structures of both commensal and pathogenic 
bacteria, are produced by mammalian gastro-
intestinal cells, and by various microbial spe-
cies. Furthermore, several products of micro-
bial metabolism have been shown to stimulate 
the host to produce several types of AMPs. 
The AMPs have a different spatial distribution 
throughout the gastrointestinal tract (GIT): 
the maximum antimicrobial activity level was 
found in the intestinal crypts and mucus lay-
er, while at lumen level a reduced activity was 
found (Meyer-Hoffert et al., 2008). The micro-
biota stimulates the host to produce AMPs, 
and produces AMPs itself. Lactobacillus and 
Bacillus, produce antimicrobial substances 
active against a wide range of entero-patho-
genic bacteria, both Gram positive, and Gram 
negative bacteria (Liévin-Le Moal et al., 2006). 
Lactobacillus and Bifidobacterium prevent 
Listeria infection of cultured epithelial cells 
(Sanz et al., 2007). Nevertheless, these antimi-
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crobial substances often tend to show activity 
against bacterial groups similar to the bacteria 
producer, a strategy to keep potential compet-
itors out of the niches occupied. A lower level 
of AMP transcripts might be induced by single 
bacterial species such as B. thetaiotaomicron 
(Cash et al., 2006), but the presence of the en-
tire microbial community is required to pro-
mote high and complete levels of expression. 
Moreover, the close contact of commensal bac-
teria with the intestinal epithelium seems to 
be a necessary condition for induction (Cash et 
al., 2006). Also several microbial metabolites 
have been shown in vitro to induce the expres-
sion of AMPs. The short chain fatty acids and 
lithocholic acid have been shown to induce the 
expression of a cathelicidin LL-37 (Schauber 
et al., 2003; Kida et al., 2006; Termén et al., 
2008). So, the commensal bacteria and/or their 
structural components and metabolic prod-
ucts have the ability to induce the expression 
of AMP and to promote their activation. AMP 
induction can be mediated through different 
signalling pathways, reflecting the different 
nature of inductive stimuli. Finally, the micro-
biota monitors itself modulating the mucosae 
glycosylation (Hooper et al., 2001), an import-
ant factor in the colonization of the GIT.
Antimicrobial activity peaks occurs in the intes-
tinal crypts and in the mucus layer along the 
mucosa. Given their close proximity to the un-
derlying mucosal immune system, these intes-
tinal areas play a very important role in main-
taining homeostasis. In healthy subjects, the 
intestinal epithelium is not strongly colonized 
and a lot of energy is spent both by the host 
and its microbiota in preventing colonization 
of this district. In a recent study, we demon-
strated the presence of a predator bacterium, 
Bdellovibrio bacteriovorus, in human gut micro-
bial ecosystem (Iebba et al., 2014). Predation is 
an important mechanism in nature to keep bac-
terial populations under control.
B. bacteriovorus seem to be closely associated 
with the mucosa area of healthy subjects, in 
which it probably exerts control over the col-
onization of this site. B. bacteriovorus was not 
found in the highly colonized mucosa of in-
flammatory bowel diseases (IBD) and coeliac 
disease patients, in which an extensive micro-
bial colonization occurs. 
ECOLOGICAL CONSIDErATIONS
In order to focus on and understand the guide-
lines governing the stability of the microbial 
ecosystem we must go into a discipline called 
microbial ecology, studying the microorgan-
isms, the interrelationships that exist among 
them and the specific environment where they 
live. Definitely we should consider ecological 
parameters in order to understand, and to in-
terfere with the human microbial ecosystems. 
Martin and collaborators (Martin et al., 2009) 
tried to explain the rules governing the sta-
bility of ecosystems with the “Nash Equilibri-
um”. Nash Equilibrium defines an ecosystem in 
which none of the components of the ecosys-
tem is advantaged by changing its strategy. The 
existing balance is a function of the coopera-
tion among all the members of the ecosystem 
and individual success, based on the strategic 
choices of a species, depends on the choices of 
the others. In this context, there are rules and 
limits that strongly disadvantage the transgres-
sors. Any form of life that is outside the rules, 
or deviates from equilibrium, inevitably is dis-
advantaged compared to others. Ecological the-
ories indicate that “head to head” competition 
inevitably leads to the loss of some species, and 
the community will tend to be a monoculture 
composed of the winner (with a loss of biodi-
versity). The model defined by “Nash Equilib-
rium” allows the co-evolution of organisms in 
competition, that otherwise would destroy each 
other. This also supports the idea that it is the 
overall balance of the gut microbial community 
that must be considered in the healthy status. 
The structure of the microbial community is an 
important factor that can strongly influence an 
individual’s susceptibility to specific diseases. 
The habitat where the microbial community 
resides must also be taken into account. In a 
“healthy” habitat, we find a high spatial and 
temporal heterogeneity. In order to loosen the 
competition among different strains and ob-
tain a fully colonized healthy habitat, a high 
number of genomic variants will be needed. 
Each genomic variant will colonize a different 
niche. In a balanced ecosystem, all niches will 
be occupied, and the colonization of potential 
pathogens coming with the allochthonous flo-
ra becomes difficult unless they adopt mutu-
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alistic strategies respecting the nature of the 
Nash equilibrium. Our microbial populations 
are subjected to two strong selective pressures. 
Pressure exerted by the microbiota itself, which 
tends to diversify microbial genomics in order 
to decrease the competition among them, and 
that exerted by the host that, on the contrary, 
tends to homogenize the genomes, promoting 
functional redundancy. In this way, the host en-
sures that functions exerted by the microbiota, 
important for his health, are not codified by a 
single species, but by more, evolutionarily dis-
tant, species. In this way the loss of one bacte-
rial species does not correspond to the loss of 
the function achieved by the species lost. These 
two selective pressures coexist in a healthy eco-
system in perfect forces equilibrium: the over-
running of one of the two would inevitably lead 
to an imbalance in the ecosystem, favouring 
individual genomic diversity or functional re-
dundancy. Ecological parameters computed by 
mathematical equations should be considered 
in the study of human microbial ecosystems. 
These parameters include Simpson biodiver-
sity (Hsi), reflecting the number and relative 
abundances of the bacterial species within a 
sample; Simpson evenness (Esi), reflecting the 
distribution of species density within a sample; 
Carrying capacity (Rr), reflecting the carrying 
capacity of the habitat and richness of micro-
bial community; the Gini coefficient of concen-
tration (C), reflecting the variation of the bac-
terial population structure, and should be used 
to evaluate the healthy status of the microbial 
ecosystem (Marzorati et al., 2008).
MICrOBIAL TOLErANCE AND 
PHySIOLOGICAL INFLAMMATION 
In preventing an excessive response to myriad 
microbes, an important role is played by the in-
testinal epithelium, which reads and interprets 
signals from the luminal environment through 
receptor systems such as the “Toll-like receptors 
“(TLR), and “Nucleotide-Binding Oligomeriza-
tion” (NODs) (Bertin et al., 1999; Inohara et al., 
1999; Inohara et al., 2003; Kawai et al., 2010), 
and allows the underlying mucosal immune 
system to make a continuous sampling through 
its dendritic cells (Lavelle et al., 2010). Through 
the modulation of immune responses, we pre-
vent an excessive immune response against 
bacteria of the intestinal microbiota. The rec-
ognition/binding of the host receptor proteins 
to specific microbial molecules or structures 
(PAMPs) stimulates a signalling cascade that 
ultimately involves the nuclear factor NF-kb 
(nuclear transcription factor) stimulating the 
expression of genes codifying pro-inflammato-
ry molecules (Hayden et al., 2006). In a healthy 
host the continued activation of inflammation, 
named “physiological inflammation”, is strictly 
controlled by specific mechanisms that allow a 
constricted regulation of the pro-inflammato-
ry signal, and the maintenance of homeostasis 
(Cario et al., 2002). The failure of this control 
mechanism could lead to a persistent inflam-
matory state (Haller, 2006). 
The microbiota contributes to the control of 
the immune response (homeostasis). Under 
the continuous stimulation of the various com-
ponents of the commensal bacteria, a reduced 
expression of TLRs in the intestinal epitheli-
um and a low production of inflammatory cy-
tokines occurs (Cebra, 1999). Furthermore, a 
strategic distribution of the receptor systems is 
else important for the discrimination between 
pathogenic and commensal (Neish, 2009). Im-
portant for homeostasis is the site at which the 
bacterial ligands interact with the receptor sys-
tems. When the interaction takes place in ar-
eas where the host/bacteria coexistence is not 
expected, microbes are sensed as pathogens 
and consequently an adequate inflammatory 
response is induced. 
EuBIOSIS AND DySBIOSIS 
The composition of our microbiota is influ-
enced by host genotype, environment and diet. 
Signalling molecules and metabolic products 
of the microbiota influence several intestinal 
functions: visceral-sensing, motility, digestion, 
permeability secretion, energy harvest, muco-
sal immunity, and barrier effect (Montalto et 
al., 2009). Furthermore, the components of the 
microbiota and/or the microbiome may enter 
the circulation and be transported to various 
organs affecting their functionality: brain (cog-
nitive functions), liver (lipid and drug metabo-
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lism), and pancreas (glucose metabolism), (Ko-
recka et al., 2012). The awareness that bacterial 
structural components and/or metabolites is 
sufficient to induce the development and mat-
urations of organs, and physiological processes 
in the host, makes us realize the importance 
of the microbial ecosystem in maintaining a 
healthy status. The intestinal microbial ecosys-
tem balance, called eubiosis, is a fundamental 
concept. As early as 400 B.C. Hippocrates said 
“death is in the bowels” and “poor digestion is 
the origin of all evil”. Ali Metchnikoff, who lived 
from 1845 to 1916, suggested that most disease 
begins in the digestive tract when the “good” 
bacteria are no longer able to control the “bad” 
ones. He called this condition dysbiosis, mean-
ing an ecosystem where bacteria no longer live 
together in mutual harmony. A gut microbiota 
in a eubiotic status is characterized by a pre-
ponderance of potentially beneficial species, 
belonging mainly to the two bacterial phylum 
Firmicutes and Bacteroides, while potentially 
pathogenic species, such as that belonging to 
the phyla Proteobacteria (Enterobacteriaceae) 
are present, but in a very low percentage. In 
case of dysbiosis “good bacteria” no longer con-
trol the “bad bacteria” which take over (Zhang 
et al., 2015). 
THE PHySIOLOGICAL IMPOrTANCE  
OF THE “EuBIOTIC STATuS” 
The factors that can disturb the balance of in-
testinal microbiota include: lifestyle, antibiotic 
treatments and pathogens. The importance of 
maintaining a eubiotic condition in the intes-
tinal microbial ecosystem is quickly highlight-
ed when we look at some of the deleterious 
sequelae after antibiotic treatment (Sekirov et 
al., 2010). The main consequence of antibiot-
ic treatment is the disruption of the ecosystem 
balance, leading to antibiotic-associated diar-
rhoea. The aetiopathology of diarrhoea may be 
due to the pathological proliferation of oppor-
tunistic pathogens of the endogenous microbi-
ota, such as Clostridium difficile (McFarland, 
2008) and vancomycin-resistant enterococci 
(Crouzet et al., 2015). Moreover, after antibi-
otic treatment patients are more receptive to 
infection sustained by hexogen pathogens, due 
to the loss of microbiota integrity and barrier 
function. We can emphasize that both oppor-
tunistic and exogenous pathogens benefit from 
the dysbiosis status. Additionally, it should be 
highlighted that the host response to exoge-
nous infectious agents amplifies/ promotes a 
dysbiosis status. The host responses include in-
flammation induction, leading to an alteration 
of the intestinal nutritional environment, and 
often to a secretory diarrhoea, having strong 
effects on the microbiota ecosystem. Under 
an inflammatory condition, we can observe an 
unexpected decrease in the vitality of the intes-
tinal microbiota, enhancing the availability of 
ecological niches for pathogen colonization. 
Furthermore, substances such as nitrate, S-ox-
ides, and N-oxides are generated as by-prod-
ucts of inflammation. Such compounds can 
represent a growth advantage for potential-
ly pathogenic species, such as the member of 
the Enterobacteriaceae family, in particularly 
Escherichia coli, as demonstrated in the ex-
periments carried out in mouse (Winter et al., 
2013). Facultative aerobe-anaerobe Gram-neg-
ative bacteria are usually present in low loads 
in the microbiota of healthy subjects, where 
strictly anaerobe bacteria are predominant. 
The presence of by-products generated by the 
inflammatory response promotes the growth of 
aerobic-anaerobic facultative bacteria able to 
use by-products as terminal electron acceptors 
for anaerobic respiration (Winter et al., 2013). 
Finally, diarrhoea leads to instability of the in-
digenous microbial population. Destabilization 
of the resident microbiota, resulting from an 
intestinal infection, has a negative impact both 
on its protective and immune-modulatory func-
tions, predisposing the host to more unpleasant 
infectious sequelae. Moreover, malfunction of 
the microbiota “organ” could have a negative 
impact even in distant organs. 
The incidence, morbidity, mortality and costs 
related to diseases such as Clostridium diffi-
cile (CD) infection have been increasing in the 
last decade, and CD infection is currently one 
of the most common nosocomial infections in 
the West (1-2-3). CD infection has a high inci-
dence of relapse ranging from 15 to 26% of pa-
tients (Pépin et al., 2006; Musher et al., 2005). 
Generally, disease recurrences are treated with 
repeated cycles of vancomycin, with an esti-
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mated therapy efficacy at the first administra-
tion of about 60%, which is radically reduced 
in patients with multiple recurrences (Walters 
et al., 1983; Kelly et al., 2008). At present, there 
are no standardized treatments, and there is a 
gap in the management of patients with mul-
tiple recurrences (Cohen et al., 2010). Consid-
ering these therapeutic limitations, the tech-
nique of faecal microbiota transplantation has 
been proposed in recent years in the treatment 
not only of CD recurrence (Gough et al., 2011; 
Kassam et al., 2013; Van Nood et al., 2013), but 
also of severe recurrent infections (Brandt et al., 
2012; Gallegos-Orozco et al., 2012; Neemann et 
al., 2012). There are many cases of patients with 
recurrent CD infections that have been treat-
ed with transplantation of faecal microbiota, 
and the percentage of efficacy has been greater 
than 90% (Guo et al., 2012). The faecal samples 
to be transplanted were obtained from healthy 
donors, preferring subjects closely related to 
the patient. The astonishing success achieved 
with this therapeutic strategy, an alternative 
to antibiotics, clearly shows the importance of 
a healthy/eubiotic microbial ecosystem for de-
fence against infections. Furthermore, studies 
designed to evaluate the possible use of the fae-
cal transplant are being undertaken in patients 
suffering from obesity, inflammatory bowel dis-
eases, or liver diseases. In all these pathologies a 
dysbiotic status of the intestinal microbiota was 
proved (De Palma et al., 2010; Schippa S. et al. 
2010; Parekh et al., 2015). Today, the condition 
of dysbiosis has been associated with important 
diseases. The list of disorders related to the in-
testinal microbiota is growing daily: pathologies 
are usually complex and multifactorial in terms 
of both pathogenesis and complications.
ESCHERICHIA COLI AND 
FAECALIBACTERIUM PRAUSNITZII:  
THE DySBIOTIC INDEX
Facultative anaerobic bacterial species, such 
as Escherichia coli, prevail over an inflamed in-
testine because unlike anaerobic bacteria, they 
can use the by-products of inflammation as ter-
minal electron acceptors (Winter et al., 2013). 
Studies carried out with adult and paediatric 
IBD patients have reported that mucosa-associ-
ated microbiota is significantly increased par-
ticularly in the Enterobacteriaceae family, such 
as Escherichia coli (Conte et al., 2006; Marti-
nez-Medina et al., 2014.). An E. coli increase has 
also been observed in other pathologies such as 
coeliac disease and cystic fibrosis (Schippa et 
al., 2010). Genomic characterization of muco-
sa-associated E. coli strains isolated from bi-
optic samples collected from ulcerative colitis, 
Crohn’s disease (CD) patients, and healthy sub-
jects, showed the association among particular 
of E. coli genomic variants to different type of 
IBD, and healthy controls (Schippa et al., 2009). 
Characterization of E. coli strains isolated from 
the mucosa of adult (CD) patients, led to the 
identification of a new pathotype within the 
species, named: “adherent-invasive Escherichia 
coli “(AIEC) (Darfeuille-Michaud, 2002). These 
strains act like entero-invasive pathogens, but 
with specific characteristics that differ from 
other subtypes of entero-invasive E. coli. The 
prototype strain, the first to be isolated and the 
most studied is AIEC LF82, isolated from ile-
um chronic lesions of adult CD patients (Bar-
nich, et al., 2007). The AIEC strains were iso-
lated in 60% of adult patients with CD and in 
16.7% of control subjects (Darfeuille-Michaud 
et al., 2004). This clearly indicates that the E. 
coli genomic variant, resembling AIEC strains, 
can be normally preset in a healthy subject, in 
a lower relative abundance. Such variant can 
represent pathobiont strains (Iebba et al., 2012; 
Schippa et al., 2012), whose growth is favoured 
in an inflamed habitat. A recent study on the 
characterization of E. coli strains isolated from 
CD paediatric patients indicated the presence 
of AIEC strains in both CD and non-IBD con-
trols, confirming the “pathobiont” nature of 
AIEC strains. The AIEC-like isolates were more 
abundant in CD patients indicating the positive 
selection of this variant in genetic predisposed 
subjects (Conte et al., 2014).
When dysbiosis occurs in addition to a signifi-
cant increase in E. coli, a decrease of beneficial 
species is reported too. Among beneficial spe-
cies, the relative abundance of the obligate an-
aerobe Faecalibacterium prausnitzii, a butyrate 
producer defined as an anti-inflammatory bac-
terium, is reported to be significantly reduced 
(Sokol et al., 2008). The decrease in relative 
abundance of F. prausnitzii, has been observed 
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not only in IBD patients, but also in patients 
with colorectal cancer, cystic fibrosis, and el-
derly or obese subjects (Miquel et al., 2013). The 
ratio of the relative abundances of F. prausnit-
zii/E. coli is currently used to evaluate the dys-
biosis status (Lopez-Siles et al., 2014). However, 
it should be noted that the decrease of the rela-
tive abundance of F. prausnitzii in adult CD pa-
tients is not observed in paediatric CD patients 
where a significant increase has been reported 
(Cao et al., 2014). This apparent contradiction 
could be explained as a response of the micro-
biota to contrast the inflammation, increasing/
favouring the growth of anti-inflammatory spe-
cies. The disease progression and persistence 
of inflammation drastically changes intestinal 
habitat conditions, shaping an environment no 
longer favouring F. prausnitzii growth (Duboc 
et al., 2013).
However, we should not forget that it is the 
overall composition of the intestinal microbi-
ota rather than the presence of single species 
that is relevant to the health or disease status 
of the host. Particular genomic variants could 
represent an additional risk factor increasing 
the mucosa damage and the severity of diseas-
es such as IBD. The importance of the overall 
composition of the intestinal microbiota can 
be appreciated observing the total recovery 
that has occurred in patients undergoing fae-
cal transplantation performed to restore a 
healthy community in subjects with C. difficile 
diarrhoea, where antibiotic therapies had failed 
(Cammarota et al., 2014; Kronman et al., 2014).
HuMAN VIrOME
Finally, we should always remember that the mi-
crobial ecosystems contain not only bacteria, but 
also viruses, bacteriophages and mycetes that 
strongly contribute to the maintenance of the 
balance. Metagenomic analysis demonstrated 
that a large community of viruses, most of which 
are unique to each individual, regularly colonize 
our body (Minot, et al., 2013). The human viruses 
group includes both eukaryotic and prokaryotic 
viruses. The viruses infecting eukaryotes have 
important effects on human health, whereas 
prokaryotes infecting viruses can also affect hu-
man health by impacting bacterial community 
structure and function. Therefore, the definition 
of the virome is an important step to understand 
how microbe networks influence human health 
or disease (Wylie et al., 2012). Further work is 
necessary to appreciate the virome effects on hu-
man health, immunity, and response to co-infec-
tions. It was recently reported that: “Influenza 
virus infection of intestinal cells raises the expo-
sure of galactose and mannose residues on the 
cell surface, significantly increasing bacterial 
adhesiveness, independently of their own adhe-
sive ability, indicating that influenza virus infec-
tion, could constitute an additional risk factor” 
(Aleandri et al., 2015). 
CONCLuSION
From this brief discussion, it is clear that it is 
important to have a holistic vision of our mi-
crobial ecosystem that takes into account all 
the components of the community. The mam-
mal’s intestine is a complex and rich ecosystem 
that provides multiple levels of intercellular sig-
nalling among:
1) the microbiota components,
2) the microbiota and the host,
3) the microbiota and hexogen pathogens,
4) the host and hexogen pathogens.
Understanding the communication and the 
pathways involved in these interactions is es-
sential to improve our knowledge of human 
physiology, and our ability to treat or prevent 
pathophysiological processes. The intestinal 
microbiota influences the host at every level, 
with an incredible adaptation capability to our 
lifestyles. We should not underestimate the ef-
fects/consequences of our behaviour on our mi-
crobial ecosystem, inevitably having an impact 
on our health.
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